🇰🇷 South Korea Country × Condition
hepatocellular carcinoma Clinical Trials in South Korea
Active clinical trials for hepatocellular carcinoma with research sites in South Korea. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 4 // Recruiting: 4 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
4
Recruiting Now
4
Country
🇰🇷 South Korea
Active Trials in South Korea (4)
NCT06326502 Phase 1
Recruiting
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
Enrollment
50 pts
Country
🇰🇷 South Korea
Etnova Therapeutics Corp.
View Trial → NCT06544629
Recruiting
Imjudo & Imfinzi PMS
Enrollment
246 pts
Country
🇰🇷 South Korea
AstraZeneca
View Trial → NCT06114082 Phase 2
Recruiting
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma
Enrollment
128 pts
Country
🇰🇷 South Korea
Seoul National University Hospital
View Trial → NCT05072041
Recruiting
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Enrollment
150 pts
Country
🇰🇷 South Korea
Next Biomedical Co., Ltd.
View Trial → Frequently Asked Questions
How many hepatocellular carcinoma clinical trials are active in South Korea?
There are currently 4 active clinical trials for hepatocellular carcinoma with sites in South Korea, of which 4 are actively recruiting patients.
How can I join a hepatocellular carcinoma clinical trial in South Korea?
To join a hepatocellular carcinoma clinical trial in South Korea, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in South Korea directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are hepatocellular carcinoma trials in South Korea?
Active hepatocellular carcinoma trials in South Korea span Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.